RKIP as an inflammatory and immune system modulator: implications in cancer

send to a friend share this

RKIP as an inflammatory and immune system modulator: implications in cancer

Monday, 13.01.2020

Authors and Affiliations:

Maria Gabriela-Freitas 1,2#, Joana Pinheiro 1,2#, Ana Raquel-Cunha 1,2, Diana Cardoso-Carneiro 1,2 and Olga Martinho 1,2,3

1 Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal

2 ICVS/3Bs-PT Government Associate Laboratory, 4710-057 Braga/4805-017 Guimarães, Portugal

3 Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo 14784 400, Brazil

# The authors contributed equally to the study

 

Abstract:

Raf kinase inhibitor protein (RKIP), an important modulator of intracellular signaling pathways, is commonly downregulated in multiple cancers. This reduction, or loss of expression, is correlated not only with the presence of metastasis, contributing to RKIP’s classification as a metastasis suppressor, but also with tumour aggressiveness and poor prognosis. Recent findings suggest a strong involvement of RKIP in the modulation of tumour microenvironment components, particularly by controlling the infiltration of specific immune cells and secretion of pro-metastatic factors. Additionally, RKIP interaction with multiple signalling molecules seems to potentiate its function as a regulator of inflammatory processes, mainly through stimulation of anti- or pro-inflammatory cytokines. Furthermore, RKIP is involved in the modulation of immunotherapeutic drugs response, through diverse mechanisms that sensitize cells to apoptosis. In the present review, we will provide updated information about the role of RKIP as an inflammatory and immune modulator and its potential implications in cancer will be addressed.

 

Journal: Biomolecules

 

Link: https://www.mdpi.com/2218-273X/9/12/769/htm